NORMAN, OK – In a significant leap forward for cancer research, scientists at the University of Oklahoma have uncovered a sophisticated mechanism by which an aggressive form of breast cancer manipulates the body’s own immune system to attract nerves into tumors, thereby creating conditions that may accelerate cancer growth and hinder treatment effectiveness. This discovery sheds new light on the complex interplay within the tumor microenvironment and offers a promising novel therapeutic strategy, particularly for patients battling triple-negative breast cancer (TNBC), one of the most challenging forms of the disease.
Published in the prestigious journal Cell Death & Differentiation, the study, led by Dr. Maureen Cox, an assistant professor in the Department of Microbiology and Immunology at the OU College of Medicine and a research member of OU Health Stephenson Cancer Center, addresses a long-standing question in oncology: how do extensive nerve networks, commonly found within many solid tumors, initially become integrated into the cancerous mass? While the presence of these nerves has been observed for years, the precise cellular and molecular processes driving their infiltration remained largely a mystery until now.
Unmasking the Immune System’s Unwitting Role in Tumor Innervation
A Hidden Alliance: Macrophages, BDNF, and Nerve Recruitment
The core of the OU team’s discovery lies in identifying a previously unrecognized alliance within the tumor microenvironment. Researchers found that aggressive breast cancer tumors actively recruit macrophages, a type of immune cell traditionally lauded for its crucial role in fighting infections, engulfing cellular debris, and facilitating tissue repair throughout the body. However, once these macrophages infiltrate the tumor, they undergo a sinister transformation, becoming complicit in the cancer’s agenda.
Upon entering the tumor, these co-opted macrophages begin to secrete substantial amounts of brain-derived neurotrophic factor (BDNF). BDNF is a protein primarily recognized for its vital functions in the nervous system, where it supports the growth, survival, and differentiation of nerve cells, particularly in the brain. In a stark reversal of its beneficial role, the OU study revealed that breast cancer cells cunningly exploit this very biological signal. By prompting macrophages to release BDNF within the tumor, the cancer effectively creates a chemical beacon, encouraging nearby peripheral nerves to grow directly toward and integrate into the malignant tissue.
"Macrophages are the critical source for drawing nerves into the tumor," Dr. Cox explained. "Although macrophages typically play a positive role in the body, they are facilitating a negative function in this scenario of breast cancer. This highlights the incredible adaptability of cancer cells to hijack normal biological processes for their own survival and proliferation."
This revelation is particularly significant for triple-negative breast cancer, which represents approximately 10-15% of all breast cancers. TNBC is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2), making it unresponsive to hormone therapy and HER2-targeted drugs. This lack of specific targets renders TNBC notoriously aggressive, often leading to higher recurrence rates and poorer prognoses compared to other breast cancer subtypes. Understanding novel mechanisms that drive TNBC growth and resistance is therefore paramount for developing effective treatments.
The Research Journey: From Observation to Intervention
Unraveling a Complex Biological Pathway
The journey to this discovery began with the observation that many aggressive tumors, including TNBC, are highly innervated. While the precise function of these tumor-associated nerves has been a subject of ongoing research—with hypotheses ranging from providing structural support to facilitating metastasis—the fundamental question of how they arrived there remained unanswered. Dr. Cox and her team hypothesized that components of the tumor microenvironment, the complex ecosystem surrounding the cancer cells, might be orchestrating this nerve infiltration.
Their meticulous investigations led them to focus on macrophages, abundant immune cells known to be highly plastic and capable of adopting various phenotypes depending on their microenvironment. Through a series of sophisticated cell culture experiments and genetic analyses, they observed a direct correlation between the presence of tumor-associated macrophages and increased nerve growth in experimental models of breast cancer. This observation spurred further inquiry into the specific molecular signals exchanged between these cells.
The identification of BDNF as the key mediator was a breakthrough. The researchers meticulously tracked the BDNF secretion by macrophages within the tumor context and demonstrated its direct impact on neurite (nerve fiber) outgrowth. This detailed mechanistic understanding provided a robust explanation for the phenomenon of tumor innervation, moving beyond mere correlation to establish a clear causal link.
Pre-Clinical Success: Blocking the Signal Slows Tumor Growth
With a clear understanding of the mechanism, the OU team proceeded to test a therapeutic strategy aimed at disrupting this harmful interaction. Their hypothesis was straightforward: if BDNF signaling is crucial for nerve infiltration and subsequent tumor growth, then blocking this signal should impede both processes.
They tested this strategy in mouse models of triple-negative breast cancer. The mice were treated with a drug designed to block BDNF signaling. The results were compelling: in the treated group, nerves no longer grew into the tumors, demonstrating the efficacy of the intervention in preventing innervation. More importantly, the researchers observed a significant reduction in tumor growth in these mice. This dual positive outcome—cessation of nerve infiltration and inhibition of tumor progression—underscored the therapeutic potential of targeting the BDNF pathway.
"It looks really promising that we can use this drug, which is already on the market, to target BDNF," Dr. Cox remarked, highlighting the potential for repurposing existing pharmaceutical agents. The availability of a clinically approved drug that can modulate BDNF signaling could significantly accelerate the translation of this research from the lab to the clinic, bypassing years of drug development and safety testing typically required for novel compounds.
Bridging the Gap: Evidence from Human Patients
To validate the relevance of their findings to human disease, the researchers meticulously examined data from patients diagnosed with triple-negative breast cancer. This crucial step involved analyzing patient tumor samples and clinical outcomes to determine if the biological patterns observed in mice held true in humans.
Their analysis revealed a compelling correlation: tumors from TNBC patients containing higher levels of both macrophages and BDNF were significantly linked with poorer survival rates. This epidemiological evidence strongly suggests that the mechanism identified in the mouse models—where macrophages secrete BDNF to promote nerve growth—is indeed active and clinically relevant in human triple-negative breast cancer. This convergence of pre-clinical and clinical data provides robust support for the translational potential of the OU team’s discovery.
Implications: A New Frontier in Cancer Therapy
Rethinking Cancer Treatment Strategies
The discovery from the University of Oklahoma could usher in a paradigm shift in cancer treatment. Traditionally, cancer therapies have primarily focused on directly destroying cancer cells through chemotherapy, radiation, or targeted molecular inhibitors. While effective for many, these approaches often face challenges such as drug resistance and collateral damage to healthy tissues. The OU research, however, proposes an alternative, complementary strategy: interrupting the intricate signaling pathways within the tumor microenvironment that appear to support tumor growth and progression.
By targeting the communication lines between macrophages and nerves, future therapies could potentially disarm cancer’s ability to create a supportive, pro-growth environment. This approach aligns with a broader trend in oncology towards understanding and manipulating the tumor microenvironment (TME), which includes not only cancer cells but also immune cells, fibroblasts, blood vessels, and nerves.
Boosting the Immune Response and Combating Immunosuppression
A particularly exciting aspect of the findings relates to the immune system. Dr. Cox hypothesized that these tumor-associated nerves might play a role in immunosuppression within the tumor microenvironment. "We believe that the nerves are immunosuppressive, so if we can stop the nerves from growing in the first place, maybe we can boost the immune response to help fight the cancer," she stated.
This hypothesis opens avenues for combination therapies. If tumor nerves indeed suppress the anti-tumor immune response, then blocking their infiltration could render the tumor more susceptible to existing immunotherapies, which aim to unleash the body’s own immune cells against cancer. Such a synergistic approach could significantly enhance treatment efficacy, particularly in cancers like TNBC that are often considered "cold" or less responsive to immunotherapies. By reducing nerve-mediated immunosuppression, the tumor microenvironment could be reprogrammed to become "hotter," allowing immune cells to more effectively infiltrate and eliminate cancer cells.
Beyond Breast Cancer: A Broader Impact
The OU team’s vision extends beyond breast cancer. The researchers plan to investigate whether this same mechanism of macrophage-mediated nerve infiltration through BDNF signaling is at play in other aggressive and difficult-to-treat cancers. High-grade ovarian cancer, another malignancy known for its aggressive nature and poor prognosis, is a primary candidate for their next line of inquiry. If similar mechanisms are discovered, the therapeutic strategy of blocking BDNF signaling could have far-reaching implications across multiple cancer types.
Furthermore, Dr. Cox and her colleagues are keen to delve deeper into the exact mechanisms by which nerves contribute to tumor growth. Some existing evidence suggests that nerves may stimulate the formation of new blood vessels (angiogenesis), which are crucial for supplying tumors with oxygen and essential nutrients, thereby fueling their rapid expansion. Other research posits that cancer cells might utilize nerve fibers as "highways" to migrate away from the primary tumor and metastasize to distant sites in the body, a process that is often the deadliest aspect of cancer. Understanding these downstream effects of tumor innervation will provide further targets for therapeutic intervention.
Ultimately, the overarching goal of this research is profoundly ambitious yet deeply human-centered: "Ultimately, we want to turn the anti-tumor immunity back on in cancer patients so their own immune systems can reject the tumors," Dr. Cox concluded. This vision encapsulates the promise of immunotherapy and the potential for new discoveries to unlock the body’s innate capacity to fight cancer, transforming once-deadly diagnoses into manageable conditions.
Acknowledgement of Support
This transformative research was made possible through significant support from various esteemed institutions. The National Institute of General Medical Sciences of the NIH provided crucial funding under award numbers P20GM103447 and P20GM103639. Additional pivotal support came from Oklahoma’s Tobacco Settlement Endowment Trust (TSET), a primary funder of the Stephenson Cancer Center and TSET Health Promotion Research Center at the University of Oklahoma. Further backing was provided by the Oklahoma Shared Clinical and Translational Resources through an Institutional Development Award from the National Institute of General Medical Sciences (grant no. U54GM104938). This collaborative funding environment underscores the importance of sustained investment in fundamental and translational research to advance human health and combat devastating diseases like cancer.
About the Author
